Pediatric Data Planning Should Start While Adult Drug Development Is In Its Infancy
Innovative trial designs and biostatistics can make pediatric drug development more efficient, but strategies like extrapolating adult data using bridging biomarkers or Bayesian analyses have complex data requirements that demand coordination and forethought.
You may also be interested in...
Behind FDA’s decision to call, and then to call off, an advisory committee for pediatric use of Viatris’ Revatio (sildenafil) in pulmonary arterial hypertension lies a debate going back more than a decade, review documents show.
Keeping Track: Pediatric Approvals, Seres Starts C Diff Submission, And BMS Pulls Reblozyl sBLA Before Possible CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The latest drug development news and highlights from our US FDA Performance Tracker.